Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User - Global Forecast to 2025
[241 Pages Report] The global therapeutic drug monitoring market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025. The emerging economies such as India and China are expected to provide a wide range of growth opportunities for players in the market which is driven by rise in the cases of chronic diseases such as cancer in these countries.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID -19 IMPACT ON THE THERAPEUTIC DRUG MONITORING MARKET
The outbreak of COVID is anticipated to drive the demand for equipment being used in TDM. Researchers have been focusing on testing a variety of potential drugs to find a suitable treatment for COVID-19. To support laboratories with this challenge, players operating in the TDM market are providing controls and calibrators. For instance, Chromsystems offers 3PLUS1 calibrator and MassCheck controls that can be used for the testing of a broad range of drugs suitable for the treatment of COVID-19.
A rising hospitalization rate due to the rapid transmission of COVID-19 has supported the growth of the hospital laboratories segment. This is mainly due to the increasing number of cases being admitted and the concomitant increase in testing volumes.
Market Dynamics
DRIVER: importance of TDM in organ transplant procedures
Conducting TDM for immunosuppressive medications is an essential tool in the management of patients undergoing solid organ transplantation. A person receiving an organ transplant is prescribed immunosuppressants so that the body does not reject the organ. When administering immunosuppressants, clinicians need to individualize a patient’s drug therapy and ensure an optimal balance between therapeutic efficacy and the probability of adverse effects. Patients present different pharmacodynamics and pharmacokinetics, so achieving this goal with immunosuppressant therapy monitoring can be challenging.
TDM is used before administering immunosuppressants as it minimizes the pharmacokinetic component of variability. Improper drug concentrations in immunosuppressants can lead to adverse effects on transplant patients. Supra-therapeutic drug concentrations can put the patient at risk of over-immunosuppression, which may cause infection. On the other hand, sub-therapeutic drug concentrations can cause the recipient’s body to reject an allograft. This inter-individual variability in drug concentrations creates the need for TDM.
BURNING ISSUES: Requirement of high capital investment
A clinical chemistry analyzer, on average, costs between USD 200,000 and USD 600,000. While fully automated analyzers are available at low prices, the variable costs of the reagents needed, and those fixed by the suppliers thereof, add to the overall expenditure. Furthermore, maintenance and insurance, laboratory supervision, and overhead (including utilities, space, and administration) are also additional expenses. The high-volume clinical chemistry analyzers may be affordable only for large hospitals and reference laboratories with good capital budgets. Most small laboratories, physicians’ offices, and sole practitioners have no capital budgets and may not be able to afford a large or very large-sized analyzer. Thus, the high fixed cost requirements limit the growth of the TDM market.
OPPORTUNITY: Increasing adoption in the treatment of autoimmune diseases
TDM is being used for Methotrexate (MTX), a folic acid analog used as a therapeutic agent for the treatment of autoimmune disease. MTX was initially used at low doses to treat chronic autoimmune disorders such as RA and Crohn’s disease. Owing to its low cost, safety, effectiveness, and clinical history, MTX is the first-line treatment for RA. However, nearly 40% of patients with RA do not respond to MTX or show clinical improvement. The reasons for non-response include a variation between patients in MTX uptake or metabolism, non-compliance with the drug regimen, or prescription of insufficient MTX dose. TDM for MTX targets measures the level of MTX-PGs in the blood cells of patients with RA and correlates these levels with response to therapy, which shows its potential applications in the area.
“Consumables segment is expected to hold the largest share of the market in 2020”
On the basis of product, the therapeutic drug monitoring market is segmented into consumables and equipment. In 2019, consumables segment accounted for the largest market share, primarily due to the repeat purchases of kits and reagents and the increasing number of immunoassay tests being performed across the globe.
“Immunoassayssegment is expected to hold the largest share of the market in 2020”
On the basis of technology, the therapeutic drug monitoring market is segmented into immunoassays and chromatography-MS. The immunoassays segment accounted for the largest share of this market in 2019, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation.
“Antiepileptic drugssegment is expected to hold the largest share of the market in 2020”
On the basis of technology, the therapeutic drug monitoring market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs. Antiepileptics are the most commonly monitored class of drugs due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs.
“The demand for therapeutic drug monitoring is anticipated to witness considerable growth from hospital laboratories in 2019”
Based on end user, the therapeutic drug monitoring market is segmented into pharmaceutical companies, hospitals & clinics, medical device companies, food & beverage companies, and other end users. Hospitals & clinics accounted for the largest share of the therapeutic drug monitoring market in 2019. The large share of this segment can be attributed to factors such as the increasing incidence of healthcare-associated infections (HAIs), the growing number of hospitals in Asian countries, and the increasing number of surgical procedures performed.
“The demand for therapeutic drug monitoring is anticipated to witness considerable growth from hospitals & clinics in 2019”
Based on end user, the therapeutic drug monitoring market is segmented into hospital laboratories, commercial & private laboratories, and other end users. Hospital laboratories accounted for the largest share of the therapeutic drug monitoring market in 2019. The large share of this segment can be attributed to factors such as the availability of advanced healthcare facilities in hospitals and the rising incidences of chronic diseases.
To know about the assumptions considered for the study, download the pdf brochure
“North America is expected to hold the highest share in 2020”
The large share of the therapeutic drug monitoring market in North America can be attributed to the increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region, coupled with initiatives taken by different government associations,
Key Market Players
The major players operating in the therapeutic drug monitoring market include Abbott Laboratories (U.S.), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories (U.S.), bioMérieux (France), BÜHLMANN Laboratories (Switzerland), SEKISUI MEDICAL (Japan), Randox Laboratories (Ireland), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (United Kingdom), ARK Diagnostics, Inc. (U.S.), Chromsystems Instruments & Chemicals GmbH (Germany), Grifols (Spain), Exagen Inc. (U.S.), Theradiag (France), R-Biopharm AG (Germany), apDia Group (Belgium), BioTeZ Berlin-Buch GmbH (Belgium), Eagle Biosciences Inc. (U.S.), JASEM Laboratory Systems and Solutions A.S (Turkey), Aalto Scientific (U.S.), Immundiagnostik AG (Germany),and UTAK (U.S.).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2016–2025 |
|
Base Year Considered |
2019 |
|
Forecast Period |
2020–2025 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
By product, technology, class of drug, end user, and region |
|
Geographies Covered |
North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, and the RoE), APAC (Japan, China, India, and the RoAPAC), Rest of the World. |
|
Companies Covered |
Abbott Laboratories (U.S.), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories (U.S.), bioMérieux (France), BÜHLMANN Laboratories (Switzerland), SEKISUI MEDICAL (Japan), Randox Laboratories (Ireland), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (United Kingdom), ARK Diagnostics, Inc. (U.S.), Chromsystems Instruments & Chemicals GmbH (Germany), Grifols (Spain), Exagen Inc. (U.S.), Theradiag (France), R-Biopharm AG (Germany), apDia Group (Belgium), BioTeZ Berlin-Buch GmbH (Belgium), Eagle Biosciences Inc. (U.S.), JASEM Laboratory Systems and Solutions A.S (Turkey), Aalto Scientific (U.S.), Immundiagnostik AG (Germany), and UTAK (U.S.). |
This research report categorizes the therapeutic drug monitoring market into the following segments and subsegments:
Therapeutic Drug Monitoring Market, by Product
- Consumables
- Equipment
- Immunoassay Analyzers
- Chromatography & MS Detectors
- Clinical Chemistry Analyzers
Therapeutic Drug Monitoring Market, by Technology
- Immunoassays
- Chemiluminescent Immunoassays
- Flourescence Immunoassays
- Calorimetric Immunoassays
- Radioimmunoassays
- Other Immunoassays
- Chromatography-MS
- Liquid Chromatography/Mass Spectrometry (LC-MS)
- Gas Chromatography-Mass Spectrometry (GC-MS)
Therapeutic Drug Monitoring Market, by Class of Drug
- Antiepileptic Drugs
- Antiarrhythmic Drugs
- Immunosuppressant Drugs
- Antibiotic Drugs
- Bronchodilator Drugs
- Psychoactive Drugs
- Other Drug Classes
Therapeutic Drug Monitoring Market, by End User
- Hospital Laboratories
- Commercial/Private Laboratories
- Other End Users
Therapeutic Drug Monitoring Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World (RoW)
Recent developments:
- In 2020, F. Hoffmann-La Roche established its presence in Cape Town, South Africa to increase their research, development and biotech production capabilities. The site will be built, featuring laboratory, biotech production and office workspace.
- In 2019, Theradiag signed distribution agreement in China, in Hong Kong-Macao and in Taiwan, to distribute its main TRACKER range biotherapy monitoring tests. These initiatives have helped the company to hold a strong position in the Asian market.
- In 2018, ARK Diagnostics, Inc. received 510(k) clearance from FDA for the ARK Tramadol Assay.
Frequently Asked Questions (FAQ):
What are the growth opportunities in the therapeutic drug monitoring market across major regions in the future?
The increasing awareness regarding the benefits of TDM, coupled with the rise in the use of various medical fields such as, oncology and autoimmune diseases to offer growth opportunities in the market.
Emerging countries have immense opportunities for the growth and adoption of therapeutic drug monitoring products. Will this scenario continue during the next five years?
Yes, the scenario is anticipated to continue during the next five years. Developed countries such as the US, offer reimbursement for TDM tests, which is expected to help in the growth in the growth of TDM market. Whereas, in European and Asian countries, the clinical trials are expected to propel the demand for TDM products during the future years.
Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
The companies manufacturing equipment such as, immunoassays and chromatography-MS have technologically launched advanced products, which are expected to help the company hold a strong position. Similarly, companies offering consumables, have received approvals for the marketing off their products.
What are the various therapeutic drug monitoring product types and their respective market shares in the overall market?
The therapeutic drug monitoring market is based on product, is broadly segmented as, consumables and equipment. In 2019, the segment of consumables held a significant share of 76%, whereas equipment held a share of 24%.
What is the impact of COVID-19 on therapeutic drug monitoring market?
The occurrence of COVID-19 is expected to have a positive impact on the therapeutic drug monitoring market. Currently, limited research work is done on the same. However, the increasing number of clinical trials being conducted to test the appropriate treatment method for COVID patients using combination of drugs, is considered to drive the market growth. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 36)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS COVERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 LIMITATIONS OF THE CURRENT EDITION
2 RESEARCH METHODOLOGY (Page No. - 41)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
FIGURE 4 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
FIGURE 8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020 VS. 2025 (USD MILLION)
FIGURE 9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
FIGURE 10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
FIGURE 11 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE THE TDM MARKET
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG
FIGURE 12 ANTIEPILEPTIC DRUGS WILL DOMINATE THE ASIA PACIFIC MARKET IN 2019
4.3 GEOGRAPHIC SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET
FIGURE 13 CHINA TO REGISTER THE HIGHEST CAGR IN THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Importance of TDM in organ transplant procedures
FIGURE 15 NUMBER OF DECEASED DONORS AND TRANSPLANTS IN THE UK (APRIL 1, 2014–MARCH 31, 2018)
5.2.1.2 Use of TDM across various therapeutic fields
TABLE 1 CLASSES OF DRUGS THAT REQUIRE MONITORING
5.2.1.3 Increasing preference for precision medicine
5.2.1.4 Growing focus on R&D activities related to TDM
FIGURE 16 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING (2010–2019)
5.2.1.5 Technological advancements
5.2.2 RESTRAINTS
5.2.2.1 Requirement of high capital investments
5.2.2.2 Reluctance of small hospitals to offer TDM services
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing adoption in the treatment of autoimmune diseases
5.2.4 CHALLENGES
5.2.4.1 Availability of alternatives to conventional TDM
5.2.4.2 Operational barriers faced in conducting TDM tests
5.3 VALUE CHAIN ANALYSIS
FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 18 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 ECOSYSTEM ANALYSIS
FIGURE 19 ECOSYSTEM ANALYSIS OF THE OVERALL IVD MARKET
5.6 IMPACT OF COVID-19 ON THE TDM MARKET
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT (Page No. - 64)
6.1 INTRODUCTION
TABLE 2 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 3 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
6.2 CONSUMABLES
TABLE 4 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 5 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2020–2025 (USD MILLION)
6.3 EQUIPMENT
TABLE 6 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
TABLE 7 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 8 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 9 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 10 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2020–2025 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS
6.3.1.1 High efficiency of immunoassay analyzers has ensured end-user demand
TABLE 11 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 12 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2020–2025 (USD MILLION)
6.3.2 CHROMATOGRAPHY & MS DETECTORS
6.3.2.1 Technological advancements have propelled the growth of the segment
TABLE 13 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2016–2019 (USD MILLION)
TABLE 14 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY AND MS DETECTORS, BY REGION, 2020–2025 (USD MILLION)
6.3.3 CLINICAL CHEMISTRY ANALYZERS
6.3.3.1 Automation to raise preference for clinical chemistry analyzers
TABLE 15 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 16 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2020–2025 (USD MILLION)
6.4 IMPACT OF COVID-19 ON THE TDM MARKET, BY PRODUCT
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY (Page No. - 72)
7.1 INTRODUCTION
TABLE 17 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 18 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
7.2 IMMUNOASSAYS
TABLE 19 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 20 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 21 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 22 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION)
7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS
7.2.1.1 Rapid detection time and good specificity support the growth of the segment
TABLE 23 CLIA SYSTEMS AVAILABLE IN THE MARKET
TABLE 24 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION)
7.2.2 FLUORESCENCE IMMUNOASSAYS
7.2.2.1 High operability and better sensitivity of FIAs to drive market growth
TABLE 26 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 27 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION)
7.2.3 COLORIMETRIC IMMUNOASSAYS
7.2.3.1 Demand for colorimetric immunoassays to decline due to the rising preference for advanced equipment
TABLE 28 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 29 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION)
7.2.4 RADIOIMMUNOASSAYS
7.2.4.1 High sensitivity in drug detection applications supports the market for radioimmunoassays
TABLE 30 RADIOIMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 31 RADIOIMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION)
7.2.5 OTHER IMMUNOASSAYS
TABLE 32 OTHER IMMUNOASSAYS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 33 OTHER IMMUNOASSAYS MARKET, BY REGION, 2020–2025 (USD MILLION)
7.3 CHROMATOGRAPHY-MS
TABLE 34 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2019 (USD MILLION)
TABLE 35 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2025–2025 (USD MILLION)
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.1.1 High accuracy supports demand for LC-MS
TABLE 36 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 37 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2025–2025 (USD MILLION)
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.2.1 Drawbacks of GC-MS challenge market growth
TABLE 38 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 39 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2025 (USD MILLION)
8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG (Page No. - 84)
8.1 INTRODUCTION
TABLE 40 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 41 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
8.2 ANTIEPILEPTIC DRUGS
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE THE GROWTH OF THE SEGMENT
TABLE 42 LIMITATIONS OF TDM OF NEWER ANTIEPILEPTIC DRUGS
TABLE 43 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 44 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
8.3 ANTIARRHYTHMIC DRUGS
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO SUPPORT SEGMENT GROWTH
TABLE 45 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 46 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
8.4 IMMUNOSUPPRESSANT DRUGS
8.4.1 IMMUNOSUPPRESSANT DEMAND HAS RISEN DUE TO AN INCREASE IN ORGAN TRANSPLANTATION PROCEDURES
TABLE 47 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 48 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
8.5 ANTIBIOTIC DRUGS
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL THE DEMAND FOR ANTIBIOTIC DRUG MONITORING
TABLE 49 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 50 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
8.6 BRONCHODILATOR DRUGS
8.6.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES WILL ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
TABLE 51 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 52 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
8.7 PSYCHOACTIVE DRUGS
8.7.1 RISING CASES OF MENTAL ILLNESS TO DRIVE MARKET GROWTH
TABLE 53 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 54 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
8.8 OTHER DRUGS
TABLE 55 OTHER DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 56 OTHER DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
8.9 IMPACT OF COVID-19 ON THE TDM MARKET, BY CLASS OF DRUG
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER (Page No. - 94)
9.1 INTRODUCTION
TABLE 57 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 58 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
9.2 HOSPITAL LABORATORIES
9.2.1 HOSPITAL LABS HOLD THE LARGEST SHARE OF THE END-USER MARKET
TABLE 59 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2016-2019 (USD MILLION)
TABLE 60 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2025–2025 (USD MILLION)
9.3 COMMERCIAL & PRIVATE LABORATORIES
9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS SUPPORT DEMAND FOR THEIR SERVICES
TABLE 61 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2016-2019 (USD MILLION)
TABLE 62 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2025–2025 (USD MILLION)
9.4 OTHER END USERS
TABLE 63 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 64 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2020–2025 (USD MILLION)
9.5 IMPACT OF COVID-19 ON THE TDM MARKET, BY END USER
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (Page No. - 99)
10.1 INTRODUCTION
TABLE 65 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 66 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2020–2025 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 20 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
TABLE 67 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 68 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 70 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 71 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 72 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 73 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 75 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 76 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 77 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 79 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 80 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 81 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.2.1 US
10.2.1.1 Awareness regarding precision medicine to propel the TDM market in the US
TABLE 83 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
TABLE 84 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 85 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 86 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 87 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 88 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 89 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 90 US: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 91 US: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 92 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 93 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 94 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 95 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Availability of funding for research to offer growth opportunities in the Canadian market
TABLE 96 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 97 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 98 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 99 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 100 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 101 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 102 CANADA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 103 CANADA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 104 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 105 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 106 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 107 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.3 EUROPE
TABLE 108 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 109 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
TABLE 110 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 111 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 112 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 113 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 114 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 116 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 117 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 118 EUROPE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 119 EUROPE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 121 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 122 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 123 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Prevalence of chronic medical conditions such as cancer and diabetes will support the growth of the market in Germany
TABLE 124 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 125 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 126 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 127 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 128 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 129 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 130 GERMANY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 131 GERMANY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 132 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 133 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 134 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 135 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.3.2 ITALY
10.3.2.1 Rising incidences of cancer to drive demand for TDM in Italy
TABLE 136 ITALY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 137 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 138 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 139 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 140 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 141 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 142 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 143 ITALY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 144 ITALY: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 145 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 146 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 147 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 148 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Awareness regarding the benefits of TDM to accelerate its demand across various therapeutic applications
TABLE 149 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 150 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 151 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 152 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 153 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 154 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 155 FRANCE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 156 FRANCE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 157 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 158 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 159 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 160 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.3.4 SPAIN
10.3.4.1 Adoption of technologically advanced immunoassays has boosted the market in Spain
TABLE 161 SPAIN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 162 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 163 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 164 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 165 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 166 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 167 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 168 SPAIN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 169 SPAIN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 170 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 171 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 172 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 173 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.3.5 UK
10.3.5.1 Increasing cases of chronic diseases to drive the growth of the TDM market
TABLE 174 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 175 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 176 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 177 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 178 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 179 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 180 UK: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 181 UK: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 182 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 183 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 184 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 185 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 186 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 187 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 188 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 189 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 190 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 191 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 192 ROE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 193 ROE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 194 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 195 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 196 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 197 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 21 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
TABLE 198 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 199 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
TABLE 200 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 201 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 202 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 203 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 204 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 205 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 206 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 207 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 208 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 209 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 210 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 211 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 212 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 213 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Japan holds the largest share of the APAC market for therapeutic drug monitoring
TABLE 214 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
TABLE 215 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 216 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 217 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 218 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 219 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 220 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 221 JAPAN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 222 JAPAN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 223 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 224 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 225 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 226 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Rising number of organ transplants in the country will drive the growth of the TDM market
TABLE 227 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 228 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 229 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 230 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 231 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 232 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,BY TYPE, 2020–2025 (USD MILLION)
TABLE 233 CHINA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 234 CHINA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 235 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 236 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 237 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 238 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Rising incidence of cancer to propel market growth
TABLE 239 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 240 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 241 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 242 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 243 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 244 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 245 INDIA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 246 INDIA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 247 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 248 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 249 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 250 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.4.4 ROAPAC
TABLE 251 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 252 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 253 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 254 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 255 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 256 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 257 ROAPAC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 258 ROAPAC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 259 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 260 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 261 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 262 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.5 REST OF THE WORLD
10.5.1 ROW ACCOUNTS FOR THE SMALLEST SHARE OF THE OVERALL MARKET BUT IS EXPECTED TO SEE HIGH GROWTH
TABLE 263 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2019 (USD MILLION)
TABLE 264 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
TABLE 265 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 266 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 267 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2019 (USD MILLION)
TABLE 268 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
TABLE 269 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 270 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 271 ROW: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 272 ROW: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 2020–2025 (USD MILLION)
TABLE 273 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2019 (USD MILLION)
TABLE 274 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2020–2025 (USD MILLION)
TABLE 275 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 276 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2025 (USD MILLION)
10.6 IMPACT OF COVID-19 ON THE TDM MARKET, BY REGION
11 COMPETITIVE LANDSCAPE (Page No. - 179)
11.1 OVERVIEW
FIGURE 22 KEY DEVELOPMENTS IN THE THERAPEUTIC DRUG MONITORING MARKET FROM JANUARY 2017–JULY 2020
FIGURE 23 MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JULY 2020
11.2 MARKET SHARE ANALYSIS, 2019
FIGURE 24 THERAPEUTIC DRUG MONITORING MARKET SHARE ANALYSIS (2019)
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT APPROVALS
TABLE 277 KEY PRODUCT APPROVALS
11.3.2 PRODUCT LAUNCHES
TABLE 278 KEY PRODUCT LAUNCHES
11.3.3 AGREEMENTS
TABLE 279 KEY AGREEMENTS
11.3.4 EXPANSIONS
TABLE 280 KEY EXPANSIONS
11.3.5 ACQUISITIONS
TABLE 281 KEY ACQUISITIONS
11.4 COMPETITIVE LEADERSHIP MAPPING (2019)
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE COMPANIES
11.4.4 PARTICIPANTS
FIGURE 25 VENDOR COMPARISON MATRIX: THERAPEUTIC DRUG MONITORING MARKET
12 COMPANY PROFILES (Page No. - 186)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 ABBOTT LABORATORIES
FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT
12.2 THERMO FISHER SCIENTIFIC
FIGURE 27 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
12.3 F. HOFFMANN-LA ROCHE
FIGURE 28 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
12.4 SIEMENS HEALTHINEERS
FIGURE 29 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
12.5 DANAHER CORPORATION
FIGURE 30 DANAHER CORPORATION: COMPANY SNAPSHOT
12.6 BIO-RAD LABORATORIES
FIGURE 31 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
12.7 BIOMÉRIEUX
FIGURE 32 BIOMÉRIEUX: COMPANY SNAPSHOT
12.8 THERADIAG
FIGURE 33 THERADIAG: COMPANY SNAPSHOT
12.9 GRIFOLS
FIGURE 34 GRIFOLS: COMPANY SNAPSHOT
12.10 BÜHLMANN LABORATORIES
12.11 SEKISUI MEDICAL
12.12 RANDOX LABORATORIES
12.13 DIASYSTEM SCANDINAVIA
12.14 CAMBRIDGE LIFE SCIENCES
12.15 ARK DIAGNOSTICS
12.16 CHROMSYSTEMS INSTRUMENTS & CHEMICALS
12.17 EXAGEN
FIGURE 35 EXAGEN: COMPANY SNAPSHOT
12.18 R-BIOPHARM
12.19 APDIA GROUP
12.20 BIOTEZ BERLIN BUCH
12.21 EAGLE BIOSCIENCES
12.22 JASEM LABORATORY SYSTEMS AND SOLUTIONS
12.23 AALTO SCIENTIFIC
12.24 IMMUNDIAGNOSTIK
12.25 UTAK
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 ADJACENT MARKETS (Page No. - 227)
13.1 INTRODUCTION
13.2 IMMUNOASSAY MARKET
13.2.1 MARKET DEFINITION
13.2.2 LIMITATIONS
13.2.3 MARKET OVERVIEW
13.2.3.1 Introduction
13.2.3.2 Technological advancements
13.2.3.3 Growth in the biotechnology and pharmaceutical industry
13.3 IMMUNOASSAY MARKET, BY PRODUCT & SERVICE
TABLE 282 IMMUNOASSAY MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION)
13.4 IMMUNOASSAY MARKET, BY PLATFORM
TABLE 283 IMMUNOASSAY MARKET, BY PLATFORM, 2016–2023 (USD MILLION)
13.5 IMMUNOASSAY MARKET, BY TECHNOLOGY
TABLE 284 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
13.6 IMMUNOASSAY MARKET, BY SPECIMEN TYPE
TABLE 285 IMMUNOASSAY MARKET, BY SPECIMEN TYPE, 2016–2023 (USD MILLION)
13.7 IMMUNOASSAY MARKET, BY APPLICATION
TABLE 286 IMMUNOASSAY MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
13.8 IMMUNOASSAY MARKET, BY END USER
TABLE 287 IMMUNOASSAY MARKET, BY END USER, 2016–2023 (USD MILLION)
13.9 IMMUNOASSAY MARKET, BY REGION
TABLE 288 IMMUNOASSAY MARKET, BY REGION, 2016–2023 (USD MILLION)
14 APPENDIX (Page No. - 233)
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the therapeutic drug monitoring market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as therapeutic drug monitoring manufacturers, vendors, distributors, researchers, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by significant use of therapeutic drug monitoring due to the rising number of organ transplant procedures, the use of TDM across various therapeutic fields, the increasing preference for precision medicine, a growing focus on R&D related to TDM, and technological advancements in immunoassay instruments. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the therapeutic drug monitoring market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the therapeutic drug monitoring industry.
Report Objectives
- To define, describe, and forecast the therapeutic drug monitoring market on the basis of product, technology, class of drug, end user, and region.
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities, Covid-19 Impact Analysis)
- To strategically analyse micromarkets with respect to individual growth trends, prospects, and contributions to the overall therapeutic drug monitoring market
- To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments in five geographical regions, namely, North America, Europe, the Asia Pacific, and Rest of the World.
- To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies
- To track and analyse competitive developments such as product launches, partnerships, expansions, and acquisitions in the therapeutic drug monitoring market
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Geographic Analysis: Further breakdown of the Latin America, and the Middle East & African segments into their respective countries for this market
- Company Information: Detailed analysis and profiling of additional market players (up to 5)
- Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market
Get in-depth analysis of the COVID-19 impact on the Therapeutic Drug Monitoring Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Therapeutic Drug Monitoring Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Therapeutic Drug Monitoring Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Therapeutic Drug Monitoring Market